Reflex

Bringing innovation to the digital medical device market, Reflex Pro is a neurological testing and clinical support tool for medical practitioners working with concussion patients and more. Since launching Reflex in 2019, the company has experienced at least 180% growth from 2019 to 2022 and is seeking funding to scale in step with customer demand. Our team has developed what we believe is the most powerful pupillometer technology on the market – able to measure the eye’s reaction to light and provide neurological results using a mobile app in seconds. Reflex is a Class I 510(k) Exempt medical device under 21 CFR 886.1700 and should only be used by licensed medical professionals.

The patented proprietary tech behind Reflex Pro is what’s known as Software as a Medical Device (SaaMD, the company also has a standing license for all of its direct competitor's pupillometer patents). What makes the tool unique is that it doesn’t require any peripheral hardware to obtain valuable neurological vital metrics. ​​Medical personnel can download the software, create an account, and administer testing quickly, using only their smartphone.

Reflex and the company’s associated services will leverage momentum and a growing marketplace. Currently the digital health sector is expected to reach $551B by 2027, with a double-digit CAGR of 16.5%.* We are also providing a new rapid scale solution within the market for neurological biomarkers, which was valued at over $6B in 2020, and growing at a rate of 12.9%.*

In just a few short years, the Reflex team has quickly established viability, growing the company’s gross revenue by 180+% annually. A major third-party publication with a population over 20,000 proves Reflex as a biomarker of concussion, while also obtaining third-party validation in clinical studies backed by the National Institutes of Health* and the Department of Defense.*

Kurtis William SlussCEO & DirectorKurtis Sluss is an engineer, inventor, and TechCrunch Disrupt Alumnus. His background is in chemical engineering and organic chemistry from Purdue University with a focus on novel drug design and disease detection methods. An interest in advanced programming and its application in medicine led him to create a novel method to detect and classify cancerous proteins through machine learning. Now, Kurtis is translating this knowledge to neuro-biomechanical evaluations using a mobile phone. He leads Brightlamp as co-Founder and CEO to maintain the vision of creating affordable diagnostic technologies on a global scale.
Michael HeimsCFO & DirectorMichael Heims serves as the Chief Financial Officer at brightlamp. Previously to brightlamp, Michael worked at Eli Lilly and Company as a Financial Analyst managing a budget of more than $200M. Michael left Lilly to join a role with a medium-sized private equity firm, where he grew a portfolio company from $2M in EBITDA to over $30M in less than 2 years by working as the sole acquisition advisor. While there, he contributed to a variety of aspects of due diligence of prospective companies, from quality of earnings to forecasting models, and everything in between., ,